Doctors need better tools to predict which patients having liver and pancreatic surgery will have complications, and research shows that standard frailty tests miss important warning signs in these patients. According to Gram Research analysis of 232 studies, a new framework called HBP onco-frailty combines blood tests measuring nutrition and inflammation with physical fitness assessments to better identify high-risk patients. This approach helps doctors create personalized plans—including nutrition support, exercise programs, and treatment timing—to improve surgical outcomes.
Doctors use special tests to figure out which patients might have trouble after surgery. But for people having liver, bile duct, or pancreas surgery, standard tests might miss important warning signs. According to Gram Research analysis, a new framework called HBP onco-frailty combines blood tests and physical fitness checks to better predict which patients need extra help before surgery. This approach looks at nutrition, muscle strength, inflammation, and overall fitness—things that matter most for people with liver and pancreatic cancer. The goal is to help doctors prepare patients better and reduce complications after surgery.
Key Statistics
A 2026 narrative review of 232 studies found that frailty measures were generally associated with postoperative complications, delayed recovery, prolonged hospitalization, and poorer tolerance of multimodal therapy in hepatobiliary and pancreatic surgery patients.
According to research reviewed by Gram, biologically enriched frailty indices that include albumin and C-reactive protein measurements improved risk discrimination for postoperative complications compared to standard frailty tools in selected hepatobiliary and pancreatic surgery populations.
A 2026 synthesis of evidence identified four key domains of HBP onco-frailty—sarcopenia (muscle loss), malnutrition, impaired physical function, and systemic inflammation—as critical factors for predicting surgical outcomes in liver and pancreatic cancer patients.
The Quick Take
- What they studied: How to better identify which patients having liver, bile duct, or pancreas surgery are at highest risk for problems after surgery
- Who participated: Review of 232 research studies published between 2010 and 2025 examining frailty assessment in hepatobiliary and pancreatic surgery patients
- Key finding: Standard frailty tests work okay but miss important factors like inflammation and poor nutrition that are especially common in liver and pancreatic cancer patients. A new framework combining blood tests (like albumin and inflammation markers) with fitness tests works better.
- What it means for you: If you’re facing liver or pancreatic surgery, doctors may use better tests to understand your risk and create a personalized plan to strengthen you before surgery. This could mean nutrition support, exercise programs, or timing adjustments for cancer treatment.
The Research Details
This is a narrative review, which means researchers read and summarized 232 scientific studies published between January 2010 and December 2025. They searched major medical databases (PubMed, Embase, Google Scholar) and looked at reference lists from important papers. Instead of doing their own experiment, they analyzed what other researchers had already discovered about frailty—a condition where people are weak and vulnerable—in patients having liver, bile duct, and pancreas surgery.
The researchers organized their findings into four main areas: muscle loss, poor nutrition, weak physical function, and body inflammation. They looked at how well different frailty tests predicted which patients would have complications, need longer hospital stays, or struggle with cancer treatment after surgery.
This type of review is valuable because it brings together many studies to see the big picture. However, because different studies used different methods and definitions, comparing results was challenging. The researchers proposed a new framework called HBP onco-frailty that combines simple blood tests (like measuring protein and inflammation levels) with physical fitness checks.
Standard frailty tests were designed for older adults in general, but liver and pancreatic surgery patients face unique challenges. These patients often have inflammation from cancer, poor nutrition from their disease, and liver damage that affects their body’s ability to heal. A one-size-fits-all test might miss these specific problems. By creating a framework tailored to liver and pancreatic surgery, doctors can better predict complications and create targeted plans to help patients recover.
This is a narrative review, which is a summary of existing research rather than a new experiment. The strength is that it examined 232 studies and synthesized current knowledge. The limitation is that the studies reviewed used different methods and definitions, making it hard to draw firm conclusions. The researchers acknowledge that no standardized HBP-specific frailty definition exists yet. The framework proposed is meant to guide future research and clinical practice, not to be a final answer. Prospective validation studies are still needed to confirm whether this new framework actually works better in real-world settings.
What the Results Show
The review found that frailty measures—tests that assess weakness and vulnerability—are generally linked to worse outcomes after liver and pancreatic surgery. Patients identified as frail had more complications, took longer to recover, stayed in the hospital longer, and were readmitted more often. They also struggled more with multimodal therapy (combining surgery with chemotherapy or radiation).
However, the commonly used frailty tests (like the modified Frailty Index and Liver Frailty Index) may not capture the full picture for liver and pancreatic patients. These tests work reasonably well and are easy to use in clinical practice, but they don’t adequately measure inflammation and nutrition problems—two factors that are especially important in liver and pancreatic cancer.
The researchers found that adding specific blood tests improved risk prediction. Tests measuring albumin (a protein that shows nutrition status), C-reactive protein (a marker of inflammation), and the ratio between them provided better information. When combined with simple physical fitness tests, these blood markers helped doctors identify which patients were at highest risk for complications and poor recovery.
The new HBP onco-frailty framework integrates these blood tests with physical performance measures and other routine clinical information. Rather than just labeling someone as ‘frail’ or ’not frail,’ this approach provides specific information about nutrition, muscle strength, inflammation, and fitness that doctors can use to create targeted interventions.
The review identified several important secondary findings. First, the timing of frailty assessment matters—measuring frailty at different points before or after surgery can give different results. Second, there’s significant variation in how different studies define and measure frailty, making it hard to compare results across studies. Third, infection risk and cholestasis (bile buildup) are unique stressors in liver and pancreatic surgery that standard frailty tools don’t adequately address. Fourth, the review found that biologically enriched approaches—tests that include specific blood markers related to nutrition and inflammation—show promise for better risk prediction in selected patient groups.
Previous research established that frailty predicts poor surgical outcomes in general surgery and older adults. This review builds on that foundation by recognizing that liver and pancreatic surgery patients have unique biological challenges that standard frailty tests don’t fully capture. Earlier studies used generic frailty tools; this review proposes a disease-specific framework. The HBP onco-frailty approach aligns with recent trends in precision medicine—tailoring assessment and treatment to specific patient populations rather than using one-size-fits-all approaches.
The main limitation is that the 232 studies reviewed used different definitions of frailty, measured different outcomes, and assessed patients at different times. This heterogeneity makes it difficult to draw firm conclusions. Second, no standardized HBP-specific frailty definition currently exists, so the proposed framework is based on synthesizing evidence rather than on validated clinical trials. Third, most evidence comes from observational studies rather than randomized controlled trials, which limits causal conclusions. Fourth, the framework hasn’t yet been prospectively validated in large multicenter studies. The researchers acknowledge these limitations and call for future research to standardize definitions and test the framework in real-world clinical settings.
The Bottom Line
If you’re facing liver, bile duct, or pancreatic surgery, ask your surgical team about frailty assessment. Specifically, request that they measure your albumin level (nutrition status), C-reactive protein (inflammation), and assess your physical fitness. Based on these results, discuss whether you might benefit from prehabilitation (exercise and nutrition programs before surgery), nutritional support, or timing adjustments for cancer treatment. These interventions have evidence supporting their benefit. Confidence level: Moderate—the evidence supports these approaches, but the specific HBP onco-frailty framework still needs formal validation.
This framework is most relevant for patients with liver cancer, bile duct cancer, or pancreatic cancer who are candidates for surgery. It’s also important for their surgical teams, oncologists, and anesthesiologists. Patients with other types of surgery may benefit from standard frailty assessment, but this HBP-specific approach is tailored to the unique challenges of liver and pancreatic surgery. Healthy people without cancer don’t need this assessment.
If you begin prehabilitation (exercise and nutrition programs) before surgery, you might see improvements in fitness and nutrition status within 2-4 weeks. However, major improvements in muscle strength typically take 6-8 weeks. The goal is to optimize your condition before surgery to reduce complications and speed recovery. After surgery, recovery timelines vary widely depending on the extent of surgery and your baseline health.
Frequently Asked Questions
What is frailty and why does it matter before liver or pancreatic surgery?
Frailty is a state of weakness and vulnerability where your body struggles to handle stress. Before liver or pancreatic surgery, frailty predicts higher risk of complications, longer hospital stays, and slower recovery. Identifying frailty helps doctors prepare you with targeted support like nutrition and exercise programs.
What blood tests should I get before liver or pancreatic surgery?
Ask your surgical team to measure albumin (shows nutrition status), C-reactive protein (shows inflammation), and the ratio between them. These tests, combined with physical fitness assessments, help doctors better predict your surgical risk and create a personalized preparation plan.
Can prehabilitation before surgery actually improve outcomes?
Research supports that prehabilitation—exercise and nutrition programs before surgery—can improve fitness, nutrition status, and potentially reduce complications. Benefits typically appear within 2-4 weeks, with major improvements in muscle strength taking 6-8 weeks. Discuss specific prehabilitation options with your surgical team.
How is the new HBP onco-frailty framework different from standard frailty tests?
Standard frailty tests were designed for general older adults and may miss inflammation and nutrition problems that are especially common in liver and pancreatic cancer. HBP onco-frailty combines blood tests measuring these specific factors with physical fitness checks, providing a more tailored assessment for your condition.
Should I be worried if my doctor says I’m frail before surgery?
A frailty assessment isn’t a judgment—it’s a tool to identify where you need support. Being identified as frail means your surgical team can create a targeted plan including nutrition support, exercise, infection prevention, and possibly adjusted treatment timing to optimize your outcomes.
Want to Apply This Research?
- Track your albumin level and C-reactive protein results before and after any prehabilitation program. Record these blood test results monthly leading up to surgery, along with your physical fitness metrics (like how far you can walk or how many stairs you can climb without stopping).
- Use the app to schedule and log prehabilitation activities: 30 minutes of moderate exercise (walking, swimming, or cycling) at least 5 days per week, and track protein intake at meals (aim for 25-30 grams per meal). Log any infections, fatigue, or changes in appetite to share with your surgical team.
- Set up weekly reminders to log exercise minutes, protein intake, and energy levels. Create a chart showing your albumin and inflammation markers over time. Share this data with your surgical team at each appointment. After surgery, continue tracking recovery milestones: pain levels, activity tolerance, and return to normal diet.
This article summarizes a narrative review of existing research and is for educational purposes only. It does not constitute medical advice. The HBP onco-frailty framework discussed is a proposed clinical tool that has not yet been formally validated in prospective clinical trials. If you are facing liver, bile duct, or pancreatic surgery, consult with your surgical team, oncologist, and other healthcare providers about frailty assessment, prehabilitation, and personalized treatment planning. Individual assessment and recommendations should be based on your specific medical condition, imaging, laboratory results, and clinical evaluation by qualified healthcare professionals.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.